Introduction
============

In the field of toxicogenomics, various computational approaches have been developed and upgraded over the years. Nowadays, the most commonly applied method consists of the use of differential analysis, i.e., the application of statistical approaches to identify and biologically annotate differentially expressed genes (DEGs) upon compounds' perturbation ([@B25]; [@B44]). Genome-wide, unsupervised methods such as gene set enrichment analysis (GSEA), biclustering and weighted co-expression analysis (WGCNA) can be used to identify gene sets associated with specific phenotypes ([@B1]; [@B51]; [@B46]). Another branch of methods includes network-based analyses such as the clustering of gene sets based on their centrality in molecular networks ([@B26]), as well as mechanistic modeling in smaller scales such as Boolean logic modeling ([@B60]) and ordinary differential equation (ODE)-based models ([@B22])-- the latter providing dynamical information of the systems in a more refined granularity.

An important bottleneck across all methodologies, however, is the biological annotation of the gene sets. This biological annotation is provided by collections of pathways or gene sets stored in popular knowledge-driven resources such as Reactome ([@B15]) and the Gene Ontology ([@B53]). Despite the ever-increasing amount of information deposited in pathway knowledge databases, gaps on functional protein interaction and other types of biological annotation still exist. In addition, a large number of non-coding genes, i.e., small- and long- non-coding genes and pseudogenes, covering around 37,000 molecular entities whose biological roles elucidation is an ongoing task. The "biological process" branch of the Gene Ontology (GO BP) is one of the most commonly used sources of biological annotations. Nevertheless, GO BP terms only cover 33% (19,691 genes) from the entire human genome (estimated in approximately 60,200 genes according to NCBI's gene annotation) ([@B7]). On the pathway side, high-confidence databases such as Reactome comprise only around half of all human protein-coding genes (10,762 genes) ([@B15]) while low-confidence high-coverage databases such as Pathway Commons coverage for coding and non-coding portions of the genome is around 38% (22,754 genes). Furthermore, most common pathway resources only cover information regarding protein coding genes, while the role of non-coding RNAs (ncRNAs) in processes such as disease or drug response, remains uncovered. We argue here that these missing entities should not be neglected due to their potential biological functionality with respect to human health.

Community-based efforts can help to fill this gap. An example of this is the creation of GeneRIF ([@B33]), a platform to share short functional descriptions of genes which are generally observed by experimentalists. Such a database allows users to rapidly scan through the additional functional information on genes of interest which are stored in a standardized format. In parallel, user-friendly text mining tools that allow automatic retrieval of information about gene function from the literature have been developed. One such tool is PubTator ([@B57]), which supports manual literature curation besides offering a collection of annotated abstracts, including relationships among diseases, genes, and drugs. In addition, even if genes are not annotated for their biological processes, they can still be linked to verified disease signatures with, e.g., DisGeNET ([@B37]).

Besides text mining, various emerging computational approaches in Systems Biology have been developed with high potential to be applied for unveiling the functional roles of genes. For instance, the inference of transcription factor (TF) activities based on gene expression data may reflect the common regulatory patterns of signaling pathways which are shared among downstream targets with or without functional annotation ([@B4]; [@B18]). In parallel, the activity of regulatory signaling pathways can be independently predicted by computational approaches based on the expression of genes that reflect the activities of the respective pathway upon perturbation, thus highlighting possible involvement of signaling modulation via unannotated genes ([@B50]; [@B25]; [@B40]). By investigating the list of genes with unknown function which were applied to derive transcription factors' activities and signaling pathways' signatures, one could infer their biological functions associated to the role of the predicted upstream regulatory modules.

Recently, [@B46], [@B47]) have shown that gene expression in chemically exposed rats coalesce into groups of co-expressed genes (i.e., modules) -- some of which appear to be correlated to phenotypes indicative of toxicity or adverse outcomes. Interestingly, this approach highlighted branches comprising a number of modules of interest with little or no biological annotation, some of which containing ncRNAs. Their roles in cellular functioning and disease are slowly being elucidated ([@B31]; [@B58]), but their modulation upon drug exposure remains largely uncovered. In spite of that, toxicologists have pointed that their involvement in apical effects should be investigated and considered in regulatory frameworks, i.e., mode-of-action (MoA) and adverse outcome pathway (AOP) analyses ([@B2]). Studies to unveil the functionality of these poorly annotated genes are therefore necessary to generate potentially novel biomarkers to improve risk assessment during the preclinical phase. In addition, connecting the poorly annotated genes to the pathological outcomes of rodent studies will further aid to identify their function. Therefore, the identification of human orthologs is imperative to allow and improve translation of the rodent data to the human context.

Therefore, in this work we aim to assess the coverage of the current functional annotation of genes represented in public databases using toxicogenomics sets; those not found in these representative biological annotation databases were coined "dark genes" in this study. Our second goal is to (a) estimate the relevance for cellular functions of dark genes involved in drug response, and (b) assign putative functions to them. For the first task, we assess the presence of these genes in human interactomes built from several sources, in literature-based resources and their association to diseases. For the second, we employed computational approaches to identify (i) common regulatory transcription factors and (ii) signaling pathways' signatures which are shared between annotated and unannotated genes. Finally, we examine these chemical-induced changes in the light of toxicity and as potential markers of drug-induced liver injury (DILI) given their regulation in human *in vitro* and associations to pathological responses in rat *in vivo*.

Materials and Methods {#s1}
=====================

Compound Selection
------------------

In order to obtain robust modulation of genes and minimize noisy expression, we opted for analyzing inducible responses across multiple compounds. To investigate whether gene modulation of entities of interest is associated with distinct toxicities, we created two equally sized groups of chemicals to avoid sample bias, selected according to their current classification as agents involved in human DILI. For this, we used a classification based on weight of evidence of causality (DILIRank) ([@B11]), which categorize compounds in three main classes: most-DILI (drugs withdrawn or with severe DILI indication), less-DILI (drugs with mild DILI indication or adverse reactions) and no-DILI. Here, we selected compounds available on TG-GATEs either classified as most-DILI (acetaminophen, diclofenac, isoniazid, nimesulide, and valproic acid) and no-DILI (caffeine, chloramphenicol, chlorpheniramine, hydroxyzine, and theophylline) to enable an unambiguous separation of gene modulation responses. Further information on the compounds and classification proposed by [@B11] can be found in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

Gene Expression Data: Processing and Differential Gene Expression
-----------------------------------------------------------------

Gene expression data were obtained from TG-GATEs^[1](#fn01){ref-type="fn"}^ ([@B23]). Raw data files generated *in vitro* from primary human hepatocytes from each compound selected were processed (quality control, background correction, RMA normalization) using the R package affy ([@B20]). Genes were annotated with a customCDF (v. 19) with Entrez gene identifiers for Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays. Here, we opted for a traditional approach (i.e., comparison of treated vs. control mean expression) to obtain DEGs; to obtain maximal transcriptional response, we selected the highest dose and latest time point (24 h) from each compound. Differential expression analysis was then performed on each set using the R package LIMMA and comparing to time-matched controls from each compound treatment. DEGs were selected based on their significance after multiple testing correction (false discovery rate, FDR) and an absolute fold change of 1.5 (equivalent to log2 fold change of 0.585) with FDR \< 0.05.

Coverage of Biological Annotation Across Databases
--------------------------------------------------

To compute the number of DEGs that were not included in the most commonly used resources in the field of toxicology and network biology, we downloaded the files from Gene Ontology^[2](#fn02){ref-type="fn"}^ ([@B53]), Reactome^[3](#fn03){ref-type="fn"}^ ([@B15]), MSigDB ([@B29]) curated pathways^[4](#fn04){ref-type="fn"}^, Pathway Commons ^[5](#fn05){ref-type="fn"}^ ([@B10]), and OmniPath^[6](#fn06){ref-type="fn"}^ ([@B54]) on May, 2018.

We mapped the gene symbols to Entrez gene identifiers using the file <http://ftp.ncbi.nih.gov/gene/DATA/GENE_INFO/Mammalia/Homo_sapiens.gene_info.gz> downloaded on April, 2018. For those genes for which we could not find an Entrez gene identifier, we used the correspondence between UniProt identifiers and Entrez gene identifiers from the file <http://ftp.ebi.ac.uk/pub/databases/genenames/new/tsv/hgnc_complete_set.txt> downloaded on May, 2018. From the Gene Ontology file, we only took into account the GO BP branch as this branch provides a better insight into the biological mechanisms compared to molecular function (MF) and cellular component (CC). From Pathway Commons, we removed interactions without pathway annotations. From OmniPath, we removed interactions that were supported only by protein-protein interaction databases (BioGRID, HPRD, and IntAct). A DEG was tagged as dark gene if it was absent in the pathway databases and GO BP branch.

Furthermore, to assess the global coverage of the biological annotations, the same steps were performed to categorize all genes measured within the Affymetrix array platform.

Protein Interaction Networks
----------------------------

We built four protein interaction networks (PINs) using data from the most comprehensive, and updated databases: INBIOMAP ([@B28]), HIPPIE ([@B3]), BIANA ([@B19]), and IntAct ([@B36]).

To build a HIPPIE-based network, we downloaded the file [http://cbdm-01.zdv.uni-mainz.de/∼mschaefer/hippie/hippie_current.txt](http://cbdm-01.zdv.uni-mainz.de/~mschaefer/hippie/hippie_current.txt) on January, 2018. In the case of INBIOMAP, we downloaded the file from <https://www.intomics.com/inbio/map/#downloads>. We removed predicted interactions. To build an interactome from BIANA, we downloaded the *Homo sapiens* data from <http://sbi.imim.es/web/GUILDify2.php/downloads> on January, 2018. For IntAct, we downloaded the file <http://ftp.ebi.ac.uk/pub/databases/intact/current/all.zip> on October, 2017.

Literature-Based Resources
--------------------------

To provide further insight on the relevance of the role of the dark genes, we checked if they were involved in human diseases using DisGeNET data, version 5 ([@B37]). Additionally, we assessed the presence of dark genes in the scientific literature. For that goal we used GeneRIF ([@B33]), that describe in a short phrase (less than 25 characters in length) the function or functions of a gene, and PubTator ([@B57]), a web tool that supports manual literature curation using text-mining techniques.

GeneRIFs were downloaded from <http://ftp.ncbi.nih.gov/gene/GeneRIF/generifs_basic.gz> and PubTator data was downloaded from <http://ftp.ncbi.nlm.nih.gov/pub/lu/PubTator/gene2pubtator.gz> and <http://ftp.ncbi.nlm.nih.gov/pub/lu/PubTator/bioconcepts2pubtator.gz> on January 2018.

Identification of Common Regulatory Transcription Factors and Signaling Pathways
--------------------------------------------------------------------------------

The list of dark genes was mapped to the list of transcription factors and their regulated genes ("regulons") from the tool DoRothEA ([@B18]) and to the list of gene signatures used for the inference of signaling pathways' activities from the tool PROGENy ([@B40]). The mapping was classified and compared according to the group of compounds. The shared common transcription factors and signaling pathways in each group were intersected to derive the most representative proxies which represent the corresponding dark genes. Venn diagrams of these results as the ones from PINs (see section "Protein Interaction Networks") were generated with the following web tool: <http://bioinformatics.psb.ugent.be/webtools/Venn>.

Comparison to Weighted Gene Co-expression Network Analysis (WGCNA) Modules
--------------------------------------------------------------------------

Co-expression analyses aim to obtain significant relationships among genes showing similar patterns of expression across samples. The resulting gene sets (also known as modules) are useful for reducing dimensionality and correlating molecular changes to an observed phenotype. Since clusters are generated in an unbiased manner, it is possible to identify modules encompassing genes with multiple levels of biological annotation (e.g., GO terms or pathways).

To investigate the relevance of these dark genes in an animal model and its implications in adverse outcomes, we identified rat orthologs of the dark genes present in co-expression modules detected in [@B47]. The rat orthologs to human genes were then mapped to modules identified using the annotation available in the Rat Genome Database (rgd.mcw.edu). From there, modules associated with pathological outcomes and underlying GO BPs were further investigated.

Results
=======

Compound-Induced Gene Expression
--------------------------------

The number of DEGs modulated by each compound can be found in Table [1](#T1){ref-type="table"}. By merging the DEGs groupwise, a total of 5,446 and 3,845 genes were found to be induced by most-DILI and no-DILI groups, respectively, comprising in total 6,918 unique genes. These genes were classified using the Ensembl gene annotation information, which showed that the majority of all genes identified were protein coding (95%), followed by non-coding RNA (ncRNA, 4.2%), pseudogenes, snoRNA and others (less than 1% each). An overview of the number of DEGs shared by compounds from the same DILI risk group can be found in the Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

###### 

Number of differentially expressed genes (DEGs, absolute FC \> 1.5 and FDR \< 0.05) of compounds from most-DILI and no-DILI groups.

  Most-DILI               Number of DEGs   No-DILI                 Number of DEGs
  ----------------------- ---------------- ----------------------- ----------------
  Acetaminophen           2,280            Caffeine                2,316
  Diclofenac              1,888            Chloramphenicol         108
  Isoniazid               1,024            Chlorpheniramine        93
  Nimesulide              1,697            Hydroxyzine             815
  Valproic acid           2,290            Theophylline            2,918
  **Total unique DEGs**   **5,446**        **Total unique DEGs**   **3,845**

Biological Annotation and Gene Annotation of Dark Genes
-------------------------------------------------------

Among the 6,918 genes deemed significantly affected by chemical exposure, 916 genes (∼13%) were not included in any biological pathway or process. This number is lower than the number of genes in the array lacking this type of annotation, identified as 22% (4,210 out of 19,441 genes). In total, 760 out of 916 entities were categorized into gene types based on Ensembl annotation; the majority of those is considered protein coding (Table [2](#T2){ref-type="table"}). A detailed description of gene types from the array and modulated by chemicals can be found in the Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. A comparison of database coverage can be found in Supplementary Date Sheet [S1](#SM2){ref-type="supplementary-material"}. In addition, a comprehensive list encompassing gene modulation per compound/DILI risk group, as well as pathway and GO annotation and results from the methodologies applied for annotation of the dark genes is available as Supplementary Table [S1](#SM1){ref-type="supplementary-material"} while an overview of gene modulation shared across compounds from each group is available in Supplementary Data Sheet [S1](#SM2){ref-type="supplementary-material"}.

###### 

Classification of genes without GO BP annotation and absent on Reactome, MSigDB, OmniPath, and Pathway Commons databases (dark genes) modulated by compounds from most-DILI and no-DILI groups.

  Gene type              Array dark genes   Most-DILI   No-DILI   Dark DEGes
  ---------------------- ------------------ ----------- --------- ------------
  Protein coding         1,756              444         278       567
  Antisense RNA          527                69          33        78
  lincRNA                722                53          33        63
  Processed transcript   113                11          8         15
  Pseudogenes^1^         56                 18          14        25
  snoRNA                 8                  4           3         5
  Sense intronic         25                 3           1         3
  Sense overlapping      10                 1           1         2
  miRNA                  3                  1           0         1
  TEC^2^                 11                 1           1         1
  **Total**              **3231**           **605**     **372**   **760**

1

Pseudogenes from the categories "transcribed unprocessed pseudogene," "transcribed unitary pseudogene" and "transcribed processed pseudogene."

2

TEC: to be experimentally confirmed.

Characterization of Dark Genes in the Human Interactome
-------------------------------------------------------

Furthermore, we investigated the coverage of the dark genes in four different sources of human protein--protein interactions. We found 492, 420, 475, and 285 dark genes included in HIPPIE, IntAct, Inbiomap and Biana interactomes, respectively. Among them, 536 dark genes were present in at least one of these resources, while 268 were included in all four resources. The overlaps can be found in Supplementary Data Sheet [S1](#SM2){ref-type="supplementary-material"}.

We further characterized the dark genes present in the interactomes. Figure [1](#F1){ref-type="fig"} shows histograms of the degree distribution of the dark genes in each interactome. A large fraction of the dark genes has low connectivity in all four interactomes, although there are some genes with relatively high degrees. Some examples of these latter genes, more connected than the rest of dark genes in the four interactomes, are shown in Table [3](#T3){ref-type="table"}.

![Degree distribution of the dark genes in human interactome databases Biana, HIPPIE, Inbiomap, and IntAct.](fgene-09-00527-g001){#F1}

###### 

Degree of connectivity for top 10 genes in human protein--protein interaction databases.

  Gene symbol   Description                                                     BIANA   HIPPIE   INBIOMAP   IntAct
  ------------- --------------------------------------------------------------- ------- -------- ---------- --------
  *RBM12*       RNA binding motif protein 12                                    405     44       17         8
  *LRBA*        LPS responsive beige-like anchor protein                        402     28       16         9
  *SGTB*        Small glutamine rich tetratricopeptide repeat containing beta   8       87       88         177
  *TMEM25*      Transmembrane protein 25                                        3       85       77         2
  *FAM189A2*    Family with sequence similarity 189 member A2                   10      78       75         10
  *ZCCHC10*     Zinc finger CCHC-type containing 10                             51      52       53         59
  *C1orf109*    Chromosome 1 open reading frame 109                             45      51       53         116
  *TSSC4*       Tumor suppressing subtransferable candidate 4                   13      68       59         17
  *WDR26*       WD repeat domain 26                                             3       79       51         33
  *FAM90A1*     Family with sequence similarity 90 member A1                    33      49       50         122

Literature Mining: Disease Association, GeneRIF, and PubTator
-------------------------------------------------------------

We also evaluated other literature-based resources containing functional information. First, we used DisGeNET v5.0 to determine whether the dark genes are associated to human diseases. We found 60 dark genes with disease annotations reported by curated databases, and 255 dark genes in DisGeNET ALL dataset, which also includes the results from automatic text mining in the scientific literature. The top genes with disease annotations in the curated data in DisGeNET are shown in Table [4](#T4){ref-type="table"}. The diseases in which these genes were more frequently involved were different types of neoplasms, although they seem to play a role in a wide variety of diseases, and abnormal phenotypes (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}).

###### 

Top 10 genes associated to diseases in DisGeNET (curated data).

  Symbol      Description                                                                                            Gene type        DILI risk group(s)   Number of diseases
  ----------- ------------------------------------------------------------------------------------------------------ ---------------- -------------------- --------------------
  *CLIP2*     CAP-Gly domain containing linker protein 2                                                             Protein-coding   Most-DILI            141
  *IPW*       Imprinted in Prader-Willi syndrome (non-protein coding)                                                ncRNA            Most-DILI, no-DILI   66
  *TGDS*      TDP-glucose 4,6-dehydratase                                                                            Protein-coding   Most-DILI            62
  *LRBA*      LPS responsive beige-like anchor protein                                                               Protein-coding   Most-DILI            33
  *AMMECR1*   Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1   Protein-coding   Most-DILI, no-DILI   27
  *TMEM98*    Transmembrane protein 98                                                                               Protein-coding   Most-DILI            9
  *H19*       H19, imprinted maternally expressed transcript (non-protein coding)                                    ncRNA            Most-DILI            7
  *MALAT1*    Metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)                            ncRNA            Most-DILI            7
  *WDR11*     WD repeat domain 11                                                                                    Protein-coding   Most-DILI            6
  *CMYA5*     Cardiomyopathy associated 5                                                                            Protein-coding   no-DILI              3

We also evaluated the coverage of the dark genes in GeneRIF which contains users-submitted compact information regarding the function of the genes. We found 356 dark genes with GeneRIF annotations. Twenty-three dark genes had 10 or more GeneRIFs, and among those, several ncRNAs (Table [5](#T5){ref-type="table"}). Some relevant examples of the GeneRIFs for *MALAT1* are "*MALAT1* level is associated with liver damage, and has clinical utility for predicting development of hepatocellular carcinoma" or "observations suggest that *MALAT1* promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability."

###### 

Top 10 dark genes by number of GeneRIFs with their corresponding number of publications indexed on PubTator.

  Symbol      Description                                                                   Gene Type        DILI risk group(s)   GeneRIFs   Number of publications
  ----------- ----------------------------------------------------------------------------- ---------------- -------------------- ---------- ------------------------
  *H19*       H19, imprinted maternally expressed transcript (non-protein coding)           ncRNA            Most-DILI            193        1169
  *MALAT1*    Metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)   ncRNA            Most-DILI            156        1203
  *MIR29C*    microRNA 29c                                                                  ncRNA            Most-DILI            77         234
  *UCA1*      Urothelial cancer associated 1 (non-protein coding)                           ncRNA            Most-DILI, no-DILI   63         152
  *NEAT1*     Nuclear paraspeckle assembly transcript 1 (non-protein coding)                ncRNA            Most-DILI, no-DILI   56         223
  *PVT1*      Pvt1 oncogene (non-protein coding)                                            ncRNA            Most-DILI            56         182
  *TUG1*      Taurine up-regulated 1 (non-protein coding)                                   ncRNA            Most-DILI, no-DILI   41         99
  *MTUS1*     Microtubule associated scaffold protein 1                                     Protein-coding   Most-DILI, no-DILI   26         71
  *TM4SF5*    Transmembrane 4 L six family member 5                                         Protein-coding   Most-DILI, no-DILI   20         37
  *FAM167A*   Family with sequence similarity 167 member A                                  Protein-coding   Most-DILI            19         32

A similar exercise was performed using PubTator to obtain additional information with a unbiased text-mining approach. We found that 550 dark genes matched the entries in PubTator. Interestingly, the two genes with the highest number of hits were, again, two long non-coding RNAs, *MALAT1* and *H19* (Table [5](#T5){ref-type="table"}), with over 1,000 papers each. In some cases a single entry on PubTator was a match for multiple hits, as for instance "Central role of the p53 pathway in the non-coding-RNA response to oxidative stress," which related *MALAT1*, *NEAT1*, and *PVT1* (3 dark ncRNAs) to oxidative stress produced by H2O2 ([@B17]).

Mapping Functional Information of the Dark Genes With Common Regulatory TF and Signaling Pathways
-------------------------------------------------------------------------------------------------

By mapping the DEGs of the selected compounds, we found that about 16% of dark genes are the targets genes of regulatory TFs in DoRothEA (Table [6](#T6){ref-type="table"}). The intersections of regulatory TFs between most-DILI and no-DILI compounds are shown in Figure [2](#F2){ref-type="fig"}. Here, the most representative TFs for most-DILI group overlapped across all five compounds (*n* = 14) were AR, E2F1, E2F4, ETS1, FOXA1, FOXP3, GATA1, GATA2, GATA3, HNF4A, JUND, REST, SPI1, and TFAP2C, while the most representative for non-DILI group shared by all five compounds (*n* = 1) was GATA2.

###### 

Overview of mapped dark genes based on transcriptional regulation (DoRothEA) and on signaling pathway signatures (PROGENy).

  Compound              Dark genes   Dark genes in DoRothEA   Number of mapped TFs   Dark genes in PROGENy   Number of mapped signaling pathways
  --------------------- ------------ ------------------------ ---------------------- ----------------------- -------------------------------------
  Acetaminophen         294          46                       24                     11                      8
  Valproic acid         330          51                       28                     11                      6
  Isoniazid             152          22                       21                     8                       5
  Diclofenac            221          32                       26                     10                      7
  Nimesulide            145          34                       26                     5                       4
  **Total Most-DILI**   732          115                      40                     29                      10
  Theophylline          326          48                       29                     16                      6
  Caffeine              271          47                       30                     16                      7
  Hydroxyzine           81           17                       19                     3                       3
  Chloramphenicol       6            2                        4                      0                       0
  Chlorpheniramine      7            1                        1                      1                       1
  **Total No-DILI**     451          70                       36                     19                      7

![Venn diagrams showing the intersection of transcription factors (TFs) and signaling pathways regulating at least one dark gene. The number accompanying each compound refers to the number of transcription factors and signaling pathways enriched by dark genes and the intersected modules by all or most of the compounds are highlighted in the adjacent boxes. **(A,B)** Regulatory TFs of hepatotoxic and non-hepatotoxic compounds, respectively. **(C,D)** Regulatory signaling pathways of hepatotoxic and non-hepatotoxic compounds, respectively. No enriched signaling pathway was found for Chloramphenicol (absent in **D**).](fgene-09-00527-g002){#F2}

In parallel, we found that about 4% of dark genes can be grouped together with the gene signatures used for the inference of signaling pathways' activities in PROGENy (Table [6](#T6){ref-type="table"}). The most representative signaling pathways overlapped among all five most-DILI compounds (*n* = 2) were Hypoxia and PI3K, whereas TNF-alpha was the most representative one for non-DILI compounds (excluding chloramphenicol which did not have an enriched pathway), see Figure [2](#F2){ref-type="fig"}.

The scripts for all analyses conducted in this study are available in Supplementary Data Sheets [S2](#SM3){ref-type="supplementary-material"}, [S3](#SM4){ref-type="supplementary-material"}.

Rat Orthologs to Human Dark Genes in Co-expression Modules
----------------------------------------------------------

Identification of rat orthologs to human dark genes and comparison to co-expression modules generated from rats exposed to chemicals showed that 544 human dark genes had an ortholog in rat and, from these, 241 were included in at least one WGCNA module. Among these genes, at least 20 comprised those coding for transmembrane proteins (TMEM family). These dark genes were found in (1) modules from branches with global poor GO BP annotation (branches C.I and C.II indicated by [@B47]) and (2) modules associated with pathology. Table [7](#T7){ref-type="table"} contains a list of dark gene orthologs whose modules were associated with specific pathologies and the underlying GO BP (whenever available). The complete list of dark genes orthologs mapped to modules can be found in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

###### 

Orthologs to human dark genes present in modules associated to pathologies in rats described by [@B47].

  Module   Gene symbol                    Pathology association               GO-BP
  -------- ------------------------------ ----------------------------------- -------------------------------------------------------------------------------------
  13m      *Smim14*                       Adverse at 29 days, Hematopoiesis   Complement activation; Inflammatory response, Leukocyte chemotaxis
  39       *Lhfpl6*                       BDH                                 Extracellular matrix organization, Collagen fibril organization
  205      *Thyn1*                        BDH, Adverse at 29 days             Cellular response to DNA damage stimulus, Signal transduction by p53 class mediator
  293      *Magee1*                       BDH                                 --
  55m      *Abracl*                       Fibrosis, BDH, Necrosis             Membrane raft assembly, Regulation of cytoskeleton organization
  14m      *Wdr70, Lyrm1, Tmem209*        Hypertrophy                         Protein folding, tRNA metabolic process
  10       *RGD1560010, Abhd8, Tbc1d31*   Increased mitosis                   Cell cycle, Mitotic cell cycle
  81       *Jpt1*                         Increased mitosis, BDH              Actin polymerization or depolymerization
  70       *Spata2l, Ubald1*              Single cell necrosis                Cell cycle arrest
  309      *RGD1359127*                   Single cell necrosis                --
  147      *Oser1*                        Single cell necrosis                --
  27m      *C2cd2*                        Vacuolation                         

BDH, bile duct hyperplasia.

Discussion
==========

Pathway and network analyses are essential steps downstream to the identification of interesting features (e.g., differential analysis) in diverse fields of 'omics research. Despite advances in biological annotation of the human genome, there is still a considerable gap in knowledge, owed mainly to experimental evaluation of already well-studied entities, which hampers biomedical research ([@B21]). In this study, we aimed to investigate these poorly annotated entities (coined dark genes) in the light of chemical exposure since many studies in mechanistic toxicology are heavily attached to biological roles and many genes with potential mechanistic and predictive roles may remain uncovered as a result.

From our analysis, we observed that approximately 13% of DEGs and 22% of all genes in the array were not mapped to GO BP, OmniPath, MSigDB, Reactome or Pathway Commons. This finding highlights that the issue with unannotated genes is generalized and the biological functions of a number of DEGs identified in gene expression studies remain to be uncovered. Genes with Ensembl classification were mostly categorized as protein coding (73%), while 8% of dark genes were classified as long-intergenic non-coding RNA (lincRNAs), which have increasing evidences to play a role in drug-induced organ toxicity ([@B63]; [@B14]).

It was demonstrated that up to 59% of dark genes are present in at least one of the human interactome databases. Of these, a few have higher degree of connectivities to the other genes as shown in Table [3](#T3){ref-type="table"}. In the context of drug development, PINs have been employed to understand the perturbations elicited by drug treatment in cellular processes, and to characterize drug targets ([@B59]) and side effects ([@B56]). Recently, [@B38] has shown that within the set of drug targets, those that are related to side effects are more central in the interactome at local, global and meso-scale level. In the current study, we have used interactome data to highlight genes with strong molecular data, such as genes *LRBA*, which showed over 400 interaction partners in BIANA database, being associated to several diseases and involved in the response to DNA damage ([@B32]). Another example is *WDR26* -- with over 70 partners in HIPPIE database and also disease-associated, that has been found to protect cells from oxidative stress-induced apoptosis ([@B62]). Furthermore, genes such as *MYO15B, BEX5, C12orf75*, and *SPATA2L*, that appear differentially expressed in at least 4 of the 5 DILI compounds and not perturbed upon no-DILI drugs, are also involved in protein-protein interactions according to most PPI databases, thus making them interesting potential DILI biomarker candidates to further pursue.

On the other hand, the use of text mining tools allowed to obtain information about non-coding RNAs -- entities which are not included in PINs. With these methods we identified genes such as microRNA MIR29C, and non-coding RNAs H19 and MALAT1, all found exclusively in the most-DILI risk group. Deregulation of *H19* and *MALAT1* has been associated with liver disease ([@B49]). Downregulation of *H19*, which was consistently observed in all most-DILI compounds except nimesulide, has been associated with formation of Mallory-Denk bodies (MDBs), aggresomes of proteins found in many types of liver diseases ([@B35]). Furthermore, downregulation of circulating microRNAs from the mir29 family were shown in liver cirrhosis patients ([@B30]) and *MIR29C* in particular has been associated to acute and chronic models of hepatotoxicity ([@B41]). The relevance of these genes in diseases, in particular liver diseases, was demonstrated in the disease association analysis with DisGeNET (Figure [3](#F3){ref-type="fig"}). Clear associations to common compound-induced liver injuries (fatty liver, fibrosis, steatohepatitis, and cirrhosis), in addition to cancer-related processes, were observed. Drug-disease relationships are regarded as important ways to improve toxicity testing and drug safety and discovery; methods such as Connectivity map have been successfully applied to datasets, showing that correlation of 'omics' profiles between certain drugs and disease profiles recapitulate drug disease risks ([@B27]; [@B9]). Here, we show the potential of poorly annotated genes to strengthen these connections, impacting the discovery of potentially novel toxicity markers.

![Association between *H19*, *MALAT1*, and *MIR29C* and liver -related disease phenotypes.](fgene-09-00527-g003){#F3}

On another perspective, even though regulatory TF and pathway enrichment analyses have already been widely applied to many fields in biomedicine especially in cancer research ([@B12]; [@B6]), only a few case studies were shown in the field of drug safety and toxicity ([@B45]). Our unbiased enrichment analysis of regulatory TFs and pathways is one of the first studies to combine the analysis of both transcription factors and signaling pathways related to drug toxicity, especially focusing on poorly annotated entities regulated by these systems in an effort to propose additional markers of drug toxicity ([@B5]; [@B24]).

In our analyses we show that approximately 16% of the dark genes were mapped in TF-regulon database DoRothEA (Table [6](#T6){ref-type="table"}). Among the enriched TFs of dark genes in the most-DILI group, we detected, for instance, E2F1, which has been demonstrated to be involved in liver fibrosis, a common end-point of compound-induced liver injury ([@B61]), as well as JUND in the inflammatory process in liver ([@B43]). Pathways' signatures, which are largely curated and expected to represent the activity states of signaling pathways, were also found to contain approximately 4% of dark genes modulated in this study. Enriched pathways for these entities included the Hypoxia pathway, known to play a role in inflammation and fibrosis ([@B34]), PI3K pathway, that mediates liver injury in chronic fluorosis ([@B16]), as well as that of TNF-alpha pathway as the mediator of hepatotoxicity and regeneration ([@B42]), inflammation and homeostasis ([@B48]). These liver-injury mediating TFs E2F1 and JUND together with the representatives from hepatotoxic-related pathways such as HIF1A, AKT, and TNF-receptor could be perceived as potential markers to demonstrate the involvement of the dark genes in the context of DILI.

By comparing the dark genes identified in human hepatocytes to corresponding orthologs *in vivo* in a murine model, we found a consistency in the expression of these entities across species. More importantly, we show that these genes are associated with pathological outcomes (Table [7](#T7){ref-type="table"}), highlighting their potential value in pre-clinical studies. We were not able to assess the relevance of aforementioned genes linked to DILI (*MALAT1*, *H19*, and *MIR29C*) since these genes, although possessing rat orthologs, were not measured in the arrays. However, functional annotation performed *in vitro* pointed similarities to most-DILI risk -- demonstrated through genes such as *Magee1*. *Magee1* was modulated *in vitro* only by compounds in the most-DILI group, and associated to "Liver Cirrhosis, Experimental" according to DisGeNET data; *in vivo*, it was found in a module associated with hepatobiliary outcomes ([@B47]). Furthermore, genes such as *Smim14* and *Thyn1* were included in modules with biological processes; these functions may be putatively associated to these genes, as it has been shown that genes acting simultaneously often share the same biological process(es), and therefore gene co-expression networks can be used for the purpose of functional annotation ([@B55]).

By combining the results of all approaches employed in this study, we were able to find evidence in at least one approach for 701 out of the initial 916 dark genes, i.e., 76% (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Some genes were consistently found across all methodologies in addition to rat-human orthologs mapped to co-expression modules (e.g., *ST7, KLHDC2, CCDC28A, TMEM140, TRIM47*), all of which were included in clusters with GO BP annotation (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}) ([@B47]). Genes exclusively modulated by the most-DILI group with (i) hits across several methods (i.e., sum of evidences equal or higher to 8, see Supplementary Table [S1](#SM1){ref-type="supplementary-material"}) (e.g., *ST7, LRBA, TPD52L2, TSSC4, BOLA1, YIPF1, TMEM168, RSRC2, CCDC92, ITFG1, ZMYND19, TTC14*, and *TMEM9*) and (ii) moderate amount of evidence (sum equal or higher than 4) and associated with pathologies (*MAGEE1*, *TBC1D31*, *SPATA2L*, *ABHD8*, and *LHFPL6*) were also identified. Although there are reports on their involvement in different liver diseases, including non-alcoholic steatohepatitis and hepatocellular carcinoma ([@B8]; [@B64]), their roles in drug-induced organ injury has not yet been investigated. In addition to that, 215 dark genes modulated by the chemicals investigated here remain obscure -- the majority (174) being classified as ncRNAs -- which have been presented as potential non-invasive disease biomarkers ([@B52]; [@B13]). Regardless the level of findings, our results indicate concordance *in silico*, *in vitro*, and *in vivo* and potential roles in toxicity that should pave the way for further investigations aiming at the confirmation and uncovering of their biological function.

Overall, our study indicated how limitations arising from the biological annotation of genes can be minimized using a number of computational approaches, especially in the field of toxicogenomics in which uncovering and understanding of drug-gene responses is necessary to obtain novel/robust markers of toxicity. Although comprehensive databases such as Harmonizome ([@B39]) exist, they do not offer advanced mapping into the TF and pathway signatures nor cross-species concordance as performed in this study. It should also be noted that this study was based on a predefined set of approximately 19,000 genes; analyses of data from unconstrained methods (e.g., RNA-seq) using the methods described here will likely be able to provide a more accurate picture of the state of functional annotation of the whole human genome and shed light onto new, potentially relevant features in toxicological analysis.

Conclusion
==========

In summary, this study highlighted a gap in functional gene annotation in the field of toxicogenomics and presented potential methods that can generate a pipeline to fill such gap through mapping using several resources. We showed that text mining tools and biocuration offer important insights by revealing potential chemical-disease associations and functional roles. The presented microRNA, ncRNAs and regulatory transcription factors in this study may also be further investigated as potential biomarkers of DILI. Nevertheless, further experimental validation of their biological roles are still necessary not only to extend the biological knowledge beyond the scope of well-annotated entities, but in order to also fully understand their roles in toxicity and disease development which would help to unlock their prognostic and translational value.
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